Dietary patterns derived by Gaussian graphical models and metabolic profiles among overweight and obese individuals
April 5, 2025 / Metabolic syndrome / Dietary patterns / Obesity nutrition / Gaussian graphical models / Vegetable grain diet / Iranian health study
Using Gaussian graphical models, researchers found that vegetable- and grain-based dietary patterns significantly reduced metabolic syndrome risk factors, such as blood pressure and cholesterol, among overweight and obese Iranian adults.
Soybean Sprout Peptides Alleviate Obesity via PI3K-Akt and JAK-STAT Pathway Modulation, Gut Microbiota Regulation, and Metabolic Reprogramming
April 7, 2025 / Soybean sprout peptides / Obesity prevention / PI3K-Akt pathway / JAK-STAT modulation / Gut microbiota regulation / Nutraceutical development
Soybean sprout peptides reduced obesity in mice by modulating PI3K-Akt and JAK-STAT pathways, improving gut microbiota balance, and enhancing metabolic function, suggesting potential as a nutraceutical for obesity prevention and management.
“knownwell Connects with LillyDirect® to Increase Access to Independent Comprehensive Metabolic Care Options for Patients Across the U.S. “
April 2, 2025 / knownwell partnership / LillyDirect collaboration / Comprehensive metabolic care / Obesity primary care / GLP-1 obesity treatment / Telehealth metabolic services
knownwell joins LillyDirect® to expand nationwide access to comprehensive metabolic and primary care for patients with overweight and obesity, emphasizing the need for longitudinal clinical care alongside the rise of anti-obesity medications.
Gastric bypass proven most effective for severe obesity in landmark study
April 1, 2025 / Gastric bypass surgery / Severe obesity treatment / By-Band-Sleeve trial / Bariatric surgery comparison / Obesity comorbidity reduction / Cost-effective obesity care
The By-Band-Sleeve trial confirms gastric bypass as the most clinically and cost-effective surgery for severe obesity, outperforming gastric banding and sleeve gastrectomy in weight loss, comorbidity reduction, and long-term healthcare value.
Obesity severity tied to increased risk across 16 common conditions
April 6, 2024 / Obesity severity risk / Common obesity comorbidities / Sleep apnea and obesity / Type 2 diabetes risk / Metabolic liver disease / All of Us study
A Johns Hopkins-led study found that increasing obesity severity correlates with higher risks for 16 common health conditions, including sleep apnea, type 2 diabetes, and liver disease, across diverse U.S. populations in the All of Us cohort.
Menopause Raises the Risk of Fatty Liver Disease. Changing Hormones May Be the Reason Why
April 7, 2025 / Menopause fatty liver / Hormonal changes MASLD / Metabolic health menopause / Estrogen liver disease risk / Midlife women’s health / Menopause metabolic syndrome
Menopause-related hormonal shifts, particularly declining estrogen, may independently increase the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), alongside aging and lifestyle factors, according to emerging research on midlife women’s metabolic health.
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
April 1, 2025 / Revita weight maintenance / GLP-1 discontinuation obesity / Fractyl Health study / Metabolic reset therapy / Non-pharmacologic obesity treatment / FDA breakthrough device
Early REVEAL-1 data show Fractyl Health’s Revita® procedure may help prevent weight regain after GLP-1 discontinuation, offering a safe, non-pharmacologic solution to support long-term obesity management and metabolic health maintenance.
Rare sugars curb appetite and mimic diabetes drugs in mice
April 1, 2025 / Rare sugars obesity / GLP-1 secretion stimulation / D-allulose metabolic health / Type 2 diabetes intervention / Low-calorie sugar substitutes / Metabolic disease prevention
Japanese researchers found that rare sugars, particularly certain ketohexoses, stimulate GLP-1 secretion and reduce food intake in mice, suggesting their potential as low-calorie interventions for obesity, type 2 diabetes, and metabolic disease management.
Exploring the relationship between fat mass index and metabolic syndrome among cancer patients in the U.S: An NHANES analysis
April 4, 2025 / Fat mass index cancer / Metabolic syndrome survivors / NHANES cancer study / Body fat metabolic risk / Cancer survivorship health / Adiposity management strategies
NHANES analysis revealed that higher Fat Mass Index (FMI) significantly increases the risk of metabolic syndrome among U.S. cancer survivors, emphasizing the critical need for targeted adiposity management to improve long-term health outcomes in this population.
American College of Physicians announces $260,000 in grants to advance equitable obesity care
April 3, 2024 / Equitable obesity care / ACP obesity grants / Obesity stigma reduction / Physician obesity training / Community obesity education / Combatting obesity misinformation
The American College of Physicians awarded $260,000 in regional grants to advance equitable obesity care, focusing on physician education, combating stigma, addressing misinformation, and improving clinical management for patients with obesity across diverse U.S. communities.
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
April 2, 2025 / AT-7687 obesity therapy / GIPR antagonist weight loss / Antag Therapeutics clinical trial / Obesity treatment innovation / Cardiometabolic health obesity / GLP-1 combination therapy
Antag Therapeutics initiated a Phase 1a trial for AT-7687, a first-in-class GIPR antagonist designed to promote weight loss with fewer gastrointestinal side effects, aiming to enhance obesity treatment outcomes and cardiometabolic health.
Study identifies crucial gene behind metabolic liver disease
April 3, 2025 / Nwd1 gene / MASH treatment / SERCA2 ATPase / Liver disease therapy / Metabolic liver disease
Researchers at Waseda University identified the Nwd1 gene as a key driver of metabolic dysfunction-associated steatohepatitis (MASH), offering new insights into disease mechanisms and highlighting potential therapeutic targets like SERCA2 ATPase.
7 Late-Stage MASH Candidates That Could Reshape the Market
April 7, 2025 / MASH treatment pipeline / Late-stage MASH drugs / FGF21 analogs MASH / GLP-1 drugs liver disease / Metabolic liver disease market
Seven late-stage MASH therapies from companies like Akero, 89bio, and Boston Pharmaceuticals show promising approaches to metabolic liver disease, aiming to compete in a rapidly growing market projected to reach $16 billion by 2033.
Phase 3 trial of lanifibranor for MASH completes enrollment
April 7, 2025 / Lanifibranor Phase 3 / MASH clinical trial / Metabolic liver disease treatment / PPAR agonist therapy / Advanced fibrosis MASH
Inventiva completed enrollment for the Phase 3 NATiV3 trial of lanifibranor in MASH patients with advanced fibrosis, aiming to support regulatory approval for a potential new oral therapy targeting inflammation, scarring, and metabolic dysfunction.
Nutritional Wellness to Prevent Worsening of Liver Disease
April 4, 2025 / Nutritional therapy liver disease / MASLD diet strategies / MASH weight loss nutrition / Liver health dietary tips / Eating the rainbow MASLD
Experts emphasize nutritional strategies, including calorie reduction, healthier fats, and increased vegetable intake, to improve outcomes and prevent progression of metabolic-associated liver diseases like MASLD and MASH in patients at risk for serious organ damage.
Detecting and Diagnosing Metabolic Disorders
April 7, 2025 / Metabolic disorder diagnosis / Genetic metabolic diseases / Type 2 diabetes risk factors / NAFLD and metabolism / Metabolic syndrome detection
Metabolic disorders, ranging from rare inherited diseases like Gaucher and Wilson’s to common conditions like type 2 diabetes and NAFLD, arise from genetic mutations and lifestyle factors impacting nutrient processing and metabolic health.
Good metabolic health associated with less time sitting down
April 4, 2025 / Sedentary behavior metabolic health / Light physical activity benefits / Metabolic syndrome prevention / Older adult cardiovascular health / NU-AGE study findings
Reducing sedentary time, even without high-intensity exercise, significantly improves metabolic health in older adults, decreasing the risk of metabolic syndrome and supporting better cardiovascular outcomes, according to findings from the NU-AGE study.
‘We have work to do’: No weight loss benefit with semaglutide before bariatric surgery
April 4, 2025 / Semaglutide bariatric surgery / GLP-1 neoadjuvant therapy / Bariatric surgery outcomes / Weight loss surgery research / Diabetes remission bariatric care
Preoperative semaglutide did not improve weight loss, diabetes remission, or safety outcomes after bariatric surgery, suggesting timing and sequencing of GLP-1 therapy with surgery require further investigation, according to a JAMA Surgery study.
Metabolic Coordination Structures Contribute to Diabetic Myocardial Dysfunction
April 7, 2025 / Diabetic cardiac dysfunction / ACBP metabolic role / Type 2 diabetes heart disease / Cardiac remodeling diabetes / Myocardial metabolism T2DM
Researchers identified ACBP as a key mediator linking metabolic dysfunction and structural remodeling in diabetic hearts, offering a potential therapeutic target to improve cardiac function and reduce heart failure risk in patients with type 2 diabetes.
Reducing cardiometabolic risk and inflammation with pomegranate
April 4, 2025 / Pomegranate extract benefits / Cardiometabolic risk reduction / Inflammation and aging / Blood pressure natural remedies / Healthy aging nutrition
Pomegranate extract supplementation lowered systolic blood pressure and inflammatory markers like IL-6 in adults over 55, suggesting a potential non-pharmacologic strategy to reduce cardiometabolic risk and promote healthier aging.